TG Therapeutics, Inc. (NASDAQ:TGTX) is working on a subcutaneous version of BRIUMVI, which would allow for at-home administration. This new formulation is expected to open up additional market opportunities and enhance patient convenience. Moreover, management also received FDA clearance to begin studies on azer-cel, a CAR T-cell therapy for autoimmune diseases, targeting a Phase 1 study launch by early next year. Looking ahead, management has raised its full-year revenue guidance for BRIUMVI to a range of $300 million to $305 million. It is one of the 10 stocks that can make you rich in 2025. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). A bullish breakout past that line could trigger algorithmic buying from quant funds tracking biotech momentum indices.
